English Version
Logo retour accueil


Collaborative agreement with Pfizer

IntegraGen announces Collaborative Agreement with Pfizer to evaluate IntegraGen's proprietary Hepatocellular Carcinoma Molecular signature.

Collaborative agreement with Pfizer

IntegraGen and Gustave Roussy Announce High-Throughput Sequencing Unit

IntegraGen and Gustave Roussy announce the set-up of a High-Throughput Oncology Clinical Sequencing Unit.

Unit will be operated by IntegraGen within Gustave Roussy and will identify somatic genetic alterations within the whole exome of a patient’s tumor  permitting personalized cancer treatments.

Link to press release


Life Science CEO Forum in Zurich - SACHS Associates

March 4th 2014 : Integragen will present at the  "7th Annual European Life Sciences CEO Forum" on March 4th and 5th, 2014 in Zurich



IntegraGen publishes new data on genetic risk of autism

Results of a new study were published in Frontiers in Genetics which support the association of common genetic variants in the development of autism.

The study, done in partnership with external researchers in the field of autism, combined functional genomics and statistical methods to develop a gender specific genetic score for the identification of autism risk.

The research was based on results obtained from genome-wide association studies utilizing data from the Autism Genetic Resource Exchange (AGRE) and a separate independent replication sample. The study included 2,000 individuals diagnosed with ASD, as well as 600 unaffected siblings. The results of the study support the role of common variants, also known as single-nucleotide polymorphisms (SNPs), in multiplex autism families.

Press release: http://goo.gl/hixLZg 

Link to publication: http://goo.gl/5IECjD


IntegraGen donates to autism charity following 20 km of Paris race

On October 13, 2014, runners from the IntegraGen team completed the Paris 20 km race. Despite cold weather conditions, the team distinguished itself with good times.

Based on times achieved by each runner, a donation of €1,079 was made to the Roussillon Sesame Autism Association, an organiztion for parents of children with autism located in Perpignan, France.




IntegraGen to present at Autism Investment Conference

IntegraGen will be presenting during Autism Speaks' upcoming 2014 Autism Investment Conference being held on March 4th and 5th in San Francisco, California.

The company will provide an overview of the newest version of it's ARISk Autism Risk Assessment Test which is now available for pediatricians to utilize for children who have signs of developmental day or autism spectrum disorder.

2014 Autism Investment Conference

Meeting website: http://www.autismspeaks.org/aic

IntegraGen will present during the session on "Diagnostics and Risk Assessment" scheduled for Tuesday, March 4th from 10:30 a.m. to 11:15 a.m. Pacific Time. 

Potential investors interested in meeting with representatives from IntegraGen during the Autism Investment Conference can contact the company in advance by email at contact@integragen.com to arrange a meeting. 


2013 Annual Results

IntegraGen announced today the company's sales results for the year ending December 31, 2013

CA 2013: € 5.45 million
Profit up 15% compared to previous year.

Click here to view press release. 


Collaboration with New EPOC Study

IntegraGen has announced a collaboration with the team of investigators from the New EPOC study to validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).

Click here to view press release.


IntegraGen presents study data at AACAP meeting

IntegraGen presented data at the 60th Annual meeting of the American Academy of Child & Adolescent Psychiatry in Orlando, Florida reporting on the identification of over 1,500 genetic variants associated with autism.

The results of this study will be used to develop a new, broader version of the ARISk Test which will be designed to identify the risk of autism in children with signs of developmental delay or autism. 

Click here
 to view press release.


IntegraGen reports 1st half results for 2013

IntegraGen released financial results for the half year ending on June 30, 2013. Revenue grew by 18% compared to the first half of 2012.

Click here to view press release


IntegraGen obtains exclusive license for microRNA for mCRC

IntegraGen has obtained exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA which predicts progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy.

Click here to view press release


IntegraGen presents research at 2013 ASCO meeting

IntegraGen presented results on the company's latest research related to use of its proprietary microRNA biomarker to predict response to anti-EGFR therapy in KRAS wild-type metastatic colorectal cancer patients.

1. "Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastric colorectal cancer"  

2. "Hsa-miR-31-3p effects on gene expression in colorectal cell lines and patients"  


Lab21 and IntegraGen : agreement for a CE marked assay

Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic

Cambridge,UK –22nd February 2013 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

see more >

Press Release Lab21 Ltd.


Formation of Autism Community Advisory Panel

IntegraGen announced today the formation of a Community Advisory Panel to provide the company with insight and feedback on planned educational materials and informational programs directed towards the autism community.

Link to press release  

Link to list of Autism Community Advisory Panel members


Autism Parental Survey Published in Clinical Pediatrics

A new publication entitled "Parental Interest in a Genetic Risk Assessment Test for Autism Spectrum Disorders," has been published online in the journal of Clinical Pediatrics.

Link to publication


Autism center in U.S. conducting study with ARISk Test

The Knights of Columbus Developmental Center at SSM Cardinal Glennon Children's Medical Center in St. Louis, Missouri is conducting a study with the ARISk Test.  

Link to more information about study


IntegraGen announces additional financing

IntegraGen announced that the company has received €2 millions in financing from funds managed by A Plus Finance. The funds will be used to support the company's efforts with biomarker development for colorectal and liver cancer and develop/commercialization efforts in the field of autism molecular diagnostics.  

Link to press release


IntegraGen presents autism research at IMFAR

IntegraGen announced today the presentation of scientific data which demonstrates the role of common genetic variants towards the identification of risk of autism in siblings of children diagnosed with autism spectrum disorders during the 2012 International Meeting for Autism Research. 

Link to press release


Appointment of Michael Dresner

IntegraGen, Inc. Names Michael Dresner National Sales Director

Cambridge, MA (April 17, 2012) - IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISk™ Autism Risk Assessment Test. 

Link to press release 


Huge growth in Genomic Services in 2011

March 6th, : IntegraGen announces today revenues for the year ending December 31, 2011. The company also announced the signing of two pharmacogenomic contracts and the launch of a new personalized sequencing service, the first offering of this type  in France

IntegraGen becomes the first French Services Lab equipped with an Illumina MiSeq.

Huge growth in Genomic Services in 2011
Disclaimers - Mentions légales - Crédits